PATENT COOPERATION TREATY

PCT

/PTO 28 APR 2005
REC'D 1 4 OCT 2003

10/533104

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference		See Notific	ation of Transmittal of Internat	ional Pre	liminary
M915-PCT FOR	FURTHER ACTION	Examination	on Report (Form PCT/IPEA/	416)	,
International application No. PCT/JP 03/13954	tional filing date (day/mor		Priority date (day/month/ye		
International Patent Classification (IPC) or nation	al classification and IPC		L		
Int.Cl 7			•		
A61K39/00, A61K35/12	2, A61K38/17,	A61K48	/00, A61P35/00		
Applicant					
CHUGAI SEIYAKU KAI	SUSHIKI KAI	SHA			
This international preliminary examinati and is transmitted to the applicant accord	on report has been prepa ling to Article 36.	red by this Inte	ernational Preliminary Exam	ining Au	thority
2. This REPORT consists of a total of	4 sheets, incl	uding this cove	er sheet.		
This report is also accompanied by amended and are the basis for this 70.16 and Section 607 of the Adm	report and/or sheets cor	taining rectific	ations made before this Auth	vhich hav hority (se	ve been ee Rule
These annexes consist of a total of	sheets.				
3. This report contains indications relating	to the following items:				
I Basis of the report					
II Priority					
III Non-establishment of opini	on with regard to novelt	y, inventive ste	p and industrial applicability	у	
IV Lack of unity of invention					
V Reasoned statement under citations and explanations	Article 35(2) with regard supporting such stateme	l to novelty, in nt	ventive step or industrial app	licability	' ;
VI Certain documents cited					
VII Certain defects in the intern	ational application				
VIII Certain observations on the	international applicatio	n	•		
·			•		
Date of submission of the demand	De	te of completion	on of this report		
27.11.2003			24.09.2004		
Name and mailing address of the IPEA/JP	Au	thorized office	r	4C	8828
Japan Patent Office	. M (OTOHIRO	OKUBO		
3-4-3, Kasumigaseki, Chiyoda-ku, Tokyo 1	00-8915, Japan Tel	ephone No. +	81-3-3581-1101 Ext. 3	452	



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/JP 03/13954

I.	Ba	sis of the report
1.	Wit	h regard to the elements of the international application:*
	V	the international application as originally filed
		the description:
		pages, as originally filed
		pages, filed with the demand
		pages, filed with the letter of
	Ш	the claims:
	•	Nos, as originally filed
		Nos, as amended (together with any statement) under Article 19 Nos, filed with the demand
		Nos, filed with the letter of,
	\Box	the drawings:
	لـــا	sheets/figs, as originally filed
		sheets/figs, filed with the demand
		sheets/figs, filed with the letter of
		the sequence listing part of the description:
		pages, as originally filed
		pages, filed with the demand
		pages, filed with the letter of
	me i	the language, all the elements marked above were available or furnished to this Authority in the language in which international application was filed, unless otherwise indicated under this item. The elements were available or furnished to this Authority in the following language which is: The language of a translation furnished for the purposes of international search (under Rule 23.1(b)). The language of publication of the international application (under Rule 48.3(b)). The language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).
3.	With exam	regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary ination was carried out on the basis of the sequence listing:
		contained in the international application in written form.
	V	filed together with the international application in computer readable form.
		furnished subsequently to this Authority in written form.
		furnished subsequently to this Authority in computer readable form.
	Ш	The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
	V	The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4.		The amendments have resulted in the cancellation of:
,		the description, pages
		the claims, Nos.
		the drawings, sheets/figs
5.		This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
		ncement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in eport as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).
**	Any 1	replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.



International application No.
PCT/JP 03 /13954

Statement			
Novelty (N)	Claims	1-12	YE
	Claims		NO
Inventive step (IS)	Claims		YE
	Claims	1-12	NC
Industrial applicability (IA)	Claims	1-12	YE
	Claims		NC
D.4 TDFON			
I malignancies. Seminar see the whole document line 47, right column, pa lines 4-36, left column, line 10-36, left column,	rs in Oncology, c, especially age 601 to line page 604; page 605 2 A1 (CHUGA) c, especially	apeutic strategies for the trea 2000, vol.27, no.5, p.598-67 12, left column, page 602; SEIYAKU KK) 2001.10.18	atment of plasma


D1 discloses immunotherapeutic strategies including the following methods (1) to (3) f or the treatment of plasma cell malignancies such as multiple myeloma (MM):

(1) immunization with functional dendritic cells pulsed with a tumor antigen or DNA encoding a target tumor antigen (see [page 604,left column,line 4-36]),

(2) immunization directly with an target tumor antigen e.g. MM-ideotypic protein (see [p age 604, left column, line 38 - page 605, left column, line 8]) ,

(3) immunization with DNA plasmids encoding a target tumor antigen (see [page 605, le ft column, line 10-36]).





Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: V.

D1 does not concretely describe HM1.24 for the use as a target antigen for the above disclosed treatment of MM, however, D1 implies that HM1.24 would be one of the typical candidates as a target for antibody-mediated therapy of MM (see [page 599, left column, line 3 or page 601, right column, line 47 - page 602, left column, line 12]). Therefore, taking into consideration the above-mentioned implication, a person skilled in the art would easily employ either HM1.24 as a target antigen or HM1.24-encoding gene (e.g. DNAs disclosed in D2) as a gene thereof.